Author:
Trebeschi S.,Drago S.G.,Birkbak N.J.,Kurilova I.,Cǎlin A.M.,Delli Pizzi A.,Lalezari F.,Lambregts D.M.J.,Rohaan M.W.,Parmar C.,Rozeman E.A.,Hartemink K.J.,Swanton C.,Haanen J B A G,Blank C.U.,Smit E.F.,Beets-Tan R.G.H.,Aerts H.J.W.L
Funder
SURF Cooperative
Informatics Technology for Cancer Research
Quantitative Imaging Network (QIN) program
Cancer Research UK
UCLH Biomedical Research Council
Rosetrees Trust
AstraZeneca
Boehringer Ingelheim
Novartis
Eli Lilly
Roche
GlaxoSmithKline
Pfizer
Servier
MSD
BMS
Illumina
Sarah Canon Research Institute and Celgene
Reference43 articles.
1. U.S. Food and Drug Administration. Drugs (KEYTRUDA Label). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf (1 April 2019, date last accessed).
2. U.S. Food and Drug Administration. Drugs (OPDIVO Label). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s055lbl.pdf (1 April 2019, date last accessed).
3. Opdivo: EPAR—Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf (1 April 2019, date last accessed).
4. Keytruda: EPAR—Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf (1 April 2019, date last accessed).
5. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067);Wolchok;JCO,2015
Cited by
353 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献